课题基金 / 基金详情

Novel Molecular Biomarkers and Therapeutics for Colorectal Cancer

Novel Molecular Biomarkers and Therapeutics for Colorectal Cancer
结直肠癌的新型分子生物标志物和治疗方法
批准号:
10474620
负责人:
Stephen Paul Fink
金额:
$15.51万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-18 至 2023-08-31

项目摘要

项目成果

Stephen Paul Fink的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 2017年估计有135,000例新病例和50,000例死亡,结直肠癌(CRC)是第二大疾病 导致美国癌症死亡的原因。因此,需要新的方法来阐明其生物学特性。 儿童权利委员会,以确定儿童权利委员会的高危人群,制定新的和更有针对性的预防策略 并开发新的更好的治疗方法。胃肠道肿瘤病例专科计划 卓越研究(GI孢子)开展跨学科人类研究的综合领域 特别关注开发新的生物标记物和结直肠癌和食道的靶向治疗 恶性肿瘤。Markowitz博士(单位主任),内科肿瘤学家,全国翻译领域的领先科学家 CRC的研究,是大肠孢子的PI案例。斯蒂芬·芬克博士(研究专家)是一名资深成员 他是Markowitz研究小组的成员,也是GI孢子病例的完整成员。这项建议是基于 芬克博士的几项重大发现是该案继续成功的关键 GI孢子,并概述了芬克博士将在实现该计划未来研究目标方面发挥的积极作用。 芬克博士的研究与孢子项目1特别相关,该项目以预测、预测和 15-羟基前列腺素脱氢酶在治疗中的应用此外,芬克医生的 领导生物标记物开发的专业知识使他最近发现CEMIP/KIAA1199是一种 作为检测和预后的生物标志物,并作为潜在的治疗靶点。这些发现开启了 新的研究途径内的案件GI孢子。目标:作为15-PGDH研究的关键研究员,芬克博士 将直接参与:i)确定低水平的15-PGDH表达是否会识别患有 增加结直肠癌风险;ii)确定15-前列腺素脱氢酶和/或其他前列腺素途径基因的变异是否 对阿司匹林化学预防有反应的个人和癌症;以及iii)确定关键监管机构和 结肠15-前列腺素脱氢酶信号的效应物。此外,作为孢子开发项目的负责人, 关于CEMIP,芬克博士将指导研究:i)开发CEMIP的早期翻译应用 结直肠癌的检测和预后;以及ii)检测抗CEMIP抗体是否能阻断体内肿瘤的生长。 这些研究的成功将有助于:i)帮助确定普通人群中有更高风险的人 儿童疾病研究(15 和iii)为疾病治疗提供了新的治疗途径(CEMIP研究)。这个 研究专家奖将提供支持,使芬克博士能够开发新的方法和技术 以及帮助促进芬克博士的长期目标,即成为一名团队科学家,在 胃肠道孢子和肿瘤内生物标记物和治疗靶点的发现和发展 中心。
英文摘要
PROJECT SUMMARY/ABSTRACT With an estimated 135,000 new cases and 50,000 deaths in 2017, colorectal cancer (CRC) is the second leading cause of cancer mortality in the United States. Thus, new approaches are needed to elucidate the biology of CRC, to identify individuals at high risk for CRC, to develop new and better targeted strategies for preventing CRC, and to develop new and better treatments. The Case gastrointestinal cancers Specialized Program of Research Excellence (GI SPORE) conducts an integrated spectrum of transdisciplinary human research particularly focusing on developing novel biomarkers and targeted therapies for colorectal and esophageal malignancies. Dr. Markowitz (Unit Director), a medical oncologist and a leading scientist nationally in translational research of CRC, is the PI of the Case GI SPORE. Dr. Stephen Fink (the Research Specialist) is a senior member of the Markowitz research group and an integral member of the Case GI SPORE. This proposal is based on the several high impact discoveries that Dr. Fink has made that have been key to the continued success of the Case GI SPORE, and outlines the active role Dr. Fink will play in achieving the goals of future studies in the program. Dr. Fink's studies are of particular relevance to SPORE Project 1, which centers on predictive, prognostic, and therapeutic applications of 15-Hydroxyprostaglandin dehydrogenase (15-PGDH). Additionally, Dr. Fink's expertise in leading up biomarker development has resulted in his recent discovery of CEMIP/KIAA1199 as a biomarker for detection and prognosis, and as a potential therapeutic target. These findings have opened up new research avenues within the Case GI SPORE. Goals: As a key Investigator in 15-PGDH studies, Dr. Fink will be directly involved in: i) Determining if low levels of 15-PGDH expression will identify individuals with increased CRC risk; ii) Determining if variation in 15-PGDH and/or other prostaglandin pathway genes identify individuals and cancers that will respond to aspirin chemoprevention; and iii) Identifying key regulators and effectors of colon 15-PGDH signaling. Furthermore, as the lead person directing a SPORE developmental project on CEMIP, Dr. Fink will direct research studies to: i) Develop translational applications of CEMIP for early detection and prognosis of CRC; and ii) Test if anti-CEMIP antibodies can block in vivo growth of tumors. Success of these studies will: i) help identify individuals in the general population who are at increased risk for CRC (15-PGDH studies); ii) provide new strategies for CRC chemoprevention and early detection (15-PGDH and CEMIP studies); and iii) provide a new therapeutic avenue for disease treatment (CEMIP studies). The Research Specialist award will provide support to enable Dr. Fink to develop new methodologies and techniques as well as help facilitate Dr. Fink's long-term goal of being a team scientist who provides expert guidance in discovery and development of biomarkers and therapeutic targets within the GI SPORE and the Case Cancer Center.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Molecular Biomarkers and Therapeutics for Colorectal Cancer
  • 批准号:
    10246928
  • 项目类别:
  • 资助金额:
    $15.51万
  • 财政年份:
    2018
  • 负责人:
    Stephen Paul Fink
  • 依托单位:
国内基金
海外基金
Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
  • 批准号:
    81800915
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    21.0万元
  • 批准年份:
    2018
  • 负责人:
    贺祖宏
  • 依托单位:
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
  • 批准号:
    81760190
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    32.0万元
  • 批准年份:
    2017
  • 负责人:
    王璇
  • 依托单位:
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
  • 批准号:
    81600879
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    17.0万元
  • 批准年份:
    2016
  • 负责人:
    徐晓薇
  • 依托单位: